Related Experiment Video

Updated: Jan 5, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.9K

Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response

Anna Sosnowska1,2, Malgorzata Czystowska-Kuzmicz1, Jakub Golab1,3

  • 1Department of Immunology, Medical University of Warsaw, Warsaw, Poland.

Oncoimmunology
|October 25, 2019
PubMed

Insights

Ovarian cancer cells release arginase-1 (ARG1) via extracellular vesicles, suppressing T-cell immunity by depleting ʟ-arginine. ARG1 inhibitors can restore immune function, offering a potential therapeutic strategy.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Arginase-1 (ARG1) expression in the tumor microenvironment promotes immune suppression.
  • Tumor-associated ARG1 depletes ʟ-arginine, a critical nutrient for T-cell proliferation and function.

Purpose of the Study:

  • To investigate the role of extracellular vesicles (EVs) in delivering active ARG1 from ovarian carcinoma cells.
  • To determine if ARG1 delivered via EVs contributes to local and systemic immune suppression.
  • To evaluate the potential of ARG1 inhibitors in restoring anti-tumor immunity.

Main Methods:

  • Analysis of ARG1 activity in EVs derived from ovarian carcinoma cells.
  • Assessment of ʟ-arginine levels in the tumor microenvironment and systemic circulation.
  • Evaluation of T-cell function and proliferation in the presence of ARG1-carrying EVs.
  • Testing the efficacy of ARG1 inhibitors in preclinical models.

Main Results:

  • Ovarian carcinoma cells release EVs containing enzymatically active ARG1.
  • ARG1 delivered by EVs effectively depletes ʟ-arginine, impairing T-cell expansion.
  • This immunosuppression mediated by ARG1-carrying EVs affects both local and systemic immunity.
  • Inhibition of ARG1 activity reversed the immunosuppressive effects and restored T-cell function.

Conclusions:

  • Extracellular vesicles are a key mechanism for ARG1-mediated immune suppression in ovarian cancer.
  • Targeting ARG1 with inhibitors represents a promising therapeutic approach to overcome immune evasion in ovarian carcinoma.
Keywords:
ArginaseT-cells responseextracellular vesiclesimmunotherapyovarian carcinoma

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

3.0K
A Proximal Culture Method to Study Paracrine Signaling Between Cells08:17

A Proximal Culture Method to Study Paracrine Signaling Between Cells

Published on: August 28, 2018

10.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K